CymaBay Therapeutics (NASDAQ:CBAY) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01), Yahoo Finance reports.
Shares of NASDAQ:CBAY traded down $0.16 during trading on Thursday, reaching $5.50. 30,604 shares of the stock traded hands, compared to its average volume of 772,744. The stock has a 50-day moving average of $4.98 and a two-hundred day moving average of $7.57. CymaBay Therapeutics has a 52-week low of $4.23 and a 52-week high of $14.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 16.20 and a current ratio of 16.20. The stock has a market cap of $369.61 million, a P/E ratio of -4.53 and a beta of 1.25.
A number of equities analysts recently issued reports on CBAY shares. BidaskClub raised shares of CymaBay Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 23rd. Zacks Investment Research raised shares of CymaBay Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a research note on Tuesday, October 8th. Cantor Fitzgerald set a $20.00 target price on shares of CymaBay Therapeutics and gave the company a “buy” rating in a research note on Wednesday, September 18th. Evercore ISI reaffirmed a “buy” rating and set a $15.00 target price on shares of CymaBay Therapeutics in a research note on Wednesday, August 14th. Finally, ValuEngine raised shares of CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. CymaBay Therapeutics has a consensus rating of “Buy” and an average target price of $13.25.
In other news, CEO Sujal Shah purchased 5,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were purchased at an average price of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the acquisition, the chief executive officer now directly owns 111,900 shares in the company, valued at approximately $618,807. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders have bought 11,900 shares of company stock worth $59,600. Corporate insiders own 4.20% of the company’s stock.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Featured Article: Back-End Load
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.